Stress-protective effects of micronized progesterone in treatment of anxiety disorders in pregnant women after in vitro fertilisation

Aim. To study a stress-protective efficacy of micronized progesterone (MP) in pregnant women with anxiety disorders after in vitro fertilisation (IVF). Materials and methods. We conducted a prospective, comparative open-label randomized trial in two IVF-clinics. A total of 98 pregnant women after...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Natalya I. Tapilskaya, Mikhail S. Nekrasov, Inna O. Krikheli, Ksenia V. Ob'edkova, Alexander M. Gzgzyan, Igor Y. Kogan, Ruslan I. Glushakov
Formato:	article
Lenguaje:	RU
Publicado:	IP Berlin A.V. 2021
Materias:	micronized progesterone stress protection pregnancy assisted reproductive technologies Gynecology and obstetrics RG1-991
Acceso en línea:	https://doaj.org/article/fe5ffcf2f15748d2b233bf537d21d966
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fe5ffcf2f15748d2b233bf537d21d966
record_format	dspace
spelling	oai:doaj.org-article:fe5ffcf2f15748d2b233bf537d21d9662021-12-02T19:22:24ZStress-protective effects of micronized progesterone in treatment of anxiety disorders in pregnant women after in vitro fertilisation2079-56962079-583110.26442/20795696.2021.4.201091https://doaj.org/article/fe5ffcf2f15748d2b233bf537d21d9662021-09-01T00:00:00Zhttps://gynecology.orscience.ru/2079-5831/article/viewFile/80364/pdfhttps://doaj.org/toc/2079-5696https://doaj.org/toc/2079-5831Aim. To study a stress-protective efficacy of micronized progesterone (MP) in pregnant women with anxiety disorders after in vitro fertilisation (IVF). Materials and methods. We conducted a prospective, comparative open-label randomized trial in two IVF-clinics. A total of 98 pregnant women after IVF with anxiety disorders were recruited at the 9th week of pregnancy. Progesterone supplementation after IVF for luteal phase support was administered out until 9 weeks gestation. Then, after randomization, group 1 (n=35) received 400 mg per day of MP vaginally, group 2 (n=33) received 400 mg of MP orally, group 3 (n=30) was comparative for the other groups. The duration of progesterone treatment was 12 weeks. The Spielberger State Trait Anxiety Inventory (STAI), the Montgomerysberg depression rating scale (MADRS), Hospital Anxiety and Depression Scale (HADS), and the Epworth Sleepiness Questionnaires (ESQ) were used to compare maternal mood at 9 weeks (day of randomization) after delivery and at 283, 565, 847 days after randomization. Results. The mean STAI sumscore in MP-groups was significantly lower than in group 3 starting from day 565 and continued until the end of the study. There were no significant differences between vaginal and oral administration of progesterone. There were no significant differences between the mean sumscores when questioning on the HADS, MADRS and ESQ. Conclusion. Prolonged use of MP in pregnant women with anxiety disorders led to the prevention of manifestations of an increase in anxiety and depression. The stress-protective and neuromodulating properties of MP can determine additional indications for its prolonged administration in women with anxiety disorders and/or premorbid history.Natalya I. TapilskayaMikhail S. NekrasovInna O. KrikheliKsenia V. Ob'edkovaAlexander M. GzgzyanIgor Y. KoganRuslan I. GlushakovIP Berlin A.V. articlemicronized progesteronestress protectionpregnancyassisted reproductive technologiesGynecology and obstetricsRG1-991RUГинекология, Vol 23, Iss 4, Pp 346-353 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	micronized progesterone stress protection pregnancy assisted reproductive technologies Gynecology and obstetrics RG1-991
spellingShingle	micronized progesterone stress protection pregnancy assisted reproductive technologies Gynecology and obstetrics RG1-991 Natalya I. Tapilskaya Mikhail S. Nekrasov Inna O. Krikheli Ksenia V. Ob'edkova Alexander M. Gzgzyan Igor Y. Kogan Ruslan I. Glushakov Stress-protective effects of micronized progesterone in treatment of anxiety disorders in pregnant women after in vitro fertilisation
description	Aim. To study a stress-protective efficacy of micronized progesterone (MP) in pregnant women with anxiety disorders after in vitro fertilisation (IVF). Materials and methods. We conducted a prospective, comparative open-label randomized trial in two IVF-clinics. A total of 98 pregnant women after IVF with anxiety disorders were recruited at the 9th week of pregnancy. Progesterone supplementation after IVF for luteal phase support was administered out until 9 weeks gestation. Then, after randomization, group 1 (n=35) received 400 mg per day of MP vaginally, group 2 (n=33) received 400 mg of MP orally, group 3 (n=30) was comparative for the other groups. The duration of progesterone treatment was 12 weeks. The Spielberger State Trait Anxiety Inventory (STAI), the Montgomerysberg depression rating scale (MADRS), Hospital Anxiety and Depression Scale (HADS), and the Epworth Sleepiness Questionnaires (ESQ) were used to compare maternal mood at 9 weeks (day of randomization) after delivery and at 283, 565, 847 days after randomization. Results. The mean STAI sumscore in MP-groups was significantly lower than in group 3 starting from day 565 and continued until the end of the study. There were no significant differences between vaginal and oral administration of progesterone. There were no significant differences between the mean sumscores when questioning on the HADS, MADRS and ESQ. Conclusion. Prolonged use of MP in pregnant women with anxiety disorders led to the prevention of manifestations of an increase in anxiety and depression. The stress-protective and neuromodulating properties of MP can determine additional indications for its prolonged administration in women with anxiety disorders and/or premorbid history.
format	article
author	Natalya I. Tapilskaya Mikhail S. Nekrasov Inna O. Krikheli Ksenia V. Ob'edkova Alexander M. Gzgzyan Igor Y. Kogan Ruslan I. Glushakov
author_facet	Natalya I. Tapilskaya Mikhail S. Nekrasov Inna O. Krikheli Ksenia V. Ob'edkova Alexander M. Gzgzyan Igor Y. Kogan Ruslan I. Glushakov
author_sort	Natalya I. Tapilskaya
title	Stress-protective effects of micronized progesterone in treatment of anxiety disorders in pregnant women after in vitro fertilisation
title_short	Stress-protective effects of micronized progesterone in treatment of anxiety disorders in pregnant women after in vitro fertilisation
title_full	Stress-protective effects of micronized progesterone in treatment of anxiety disorders in pregnant women after in vitro fertilisation
title_fullStr	Stress-protective effects of micronized progesterone in treatment of anxiety disorders in pregnant women after in vitro fertilisation
title_full_unstemmed	Stress-protective effects of micronized progesterone in treatment of anxiety disorders in pregnant women after in vitro fertilisation
title_sort	stress-protective effects of micronized progesterone in treatment of anxiety disorders in pregnant women after in vitro fertilisation
publisher	IP Berlin A.V.
publishDate	2021
url	https://doaj.org/article/fe5ffcf2f15748d2b233bf537d21d966
work_keys_str_mv	AT natalyaitapilskaya stressprotectiveeffectsofmicronizedprogesteroneintreatmentofanxietydisordersinpregnantwomenafterinvitrofertilisation AT mikhailsnekrasov stressprotectiveeffectsofmicronizedprogesteroneintreatmentofanxietydisordersinpregnantwomenafterinvitrofertilisation AT innaokrikheli stressprotectiveeffectsofmicronizedprogesteroneintreatmentofanxietydisordersinpregnantwomenafterinvitrofertilisation AT kseniavobedkova stressprotectiveeffectsofmicronizedprogesteroneintreatmentofanxietydisordersinpregnantwomenafterinvitrofertilisation AT alexandermgzgzyan stressprotectiveeffectsofmicronizedprogesteroneintreatmentofanxietydisordersinpregnantwomenafterinvitrofertilisation AT igorykogan stressprotectiveeffectsofmicronizedprogesteroneintreatmentofanxietydisordersinpregnantwomenafterinvitrofertilisation AT ruslaniglushakov stressprotectiveeffectsofmicronizedprogesteroneintreatmentofanxietydisordersinpregnantwomenafterinvitrofertilisation
_version_	1718376774984794112

Stress-protective effects of micronized progesterone in treatment of anxiety disorders in pregnant women after in vitro fertilisation

Ejemplares similares